文献速递肝病消化道肿瘤与早癌

慢性乙型肝炎患者自发或核苷(酸)类似物诱导HBsAg清除后肝细胞癌风险均较低

Similarly low risk of hepatocellular carcinoma after either spontaneous or nucleos(t)ide analogue-induced hepatitis B surface antigen loss.
PubMed 文献 · Aliment Pharmacol Ther · 2020-11-22

这项基于香港全港数据库的回顾性队列研究纳入7124例实现HBsAg清除的成人慢性乙型肝炎患者,其中83.1%为自发清除、16.9%为核苷(酸)类似物诱导清除。中位随访4.3年,两组肝细胞癌发生率分别为1.6%和1.3%,校正后风险无显著差异(adjusted subdistribution hazard ratio 0.75,95%CI 0.43-1.32,P=0.323)。

要点

  • 慢性乙型肝炎患者无论自发还是核苷(酸)类似物诱导HBsAg清除,肝细胞癌风险均较低且相近。
  • 核苷(酸)类似物诱导清除者更年轻、男性及肝硬化比例更高,但校正后肝癌风险与自发清除者相当。
  • 研究结果在倾向评分加权和匹配分析中保持稳健。

核心结论

  • 在实现HBsAg清除的慢性乙型肝炎患者中,自发清除与核苷(酸)类似物诱导清除后的肝细胞癌风险相似且均较低。

研究设计与样本

  • 基于香港全港数据库的回顾性队列研究,纳入2000年1月至2019年3月间实现HBsAg清除的成人慢性乙型肝炎单一感染患者,排除HBsAg清除前已行肝移植或已发生肝细胞癌者。
  • 共纳入7124例患者,平均年龄58.1±13.8岁,男性4340例(60.9%),肝硬化451例(6.3%)。
  • 自发HBsAg清除5917例(83.1%),核苷(酸)类似物诱导清除1207例(16.9%)。

主要发现

  • 中位随访4.3年(四分位距2.2-7.6年),自发清除组97例(1.6%)发生肝细胞癌,核苷(酸)类似物诱导清除组16例(1.3%)发生肝细胞癌。
  • 核苷(酸)类似物诱导清除者相比自发清除者更年轻,且男性及肝硬化比例更高。
  • 核苷(酸)类似物诱导清除者肝细胞癌风险与自发清除者相当(adjusted subdistribution hazard ratio 0.75,95%CI 0.43-1.32,P=0.323)。
  • 倾向评分加权和匹配分析结果保持稳健。

临床怎么用

  • 对于实现HBsAg清除的慢性乙型肝炎患者,无论清除方式为自发还是核苷(酸)类似物诱导,均应认识到其肝细胞癌风险均较低且相近。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: It is unknown whether patients with chronic hepatitis B (CHB) who achieved hepatitis B surface antigen (HBsAg) seroclearance spontaneously or following anti-viral therapy have similar clinical outcomes. AIM: To compare the risk of hepatocellular carcinoma (HCC) in patients with CHB who either cleared HBsAg spontaneously or following anti-viral therapy METHODS: Adult CHB-monoinfected patients who cleared HBsAg between January 2000 and March 2019 were identified from a territory-wide database in Hong Kong. Patients with liver transplantation and/or HCC before HBsAg loss were excluded. Patients' demographics, comorbidities, anti-viral treatment, laboratory parameters and HCC development were analysed. RESULTS: Of 7,124 identified patients with CHB who cleared HBsAg, mean age was 58.1 ± 13.8 years; 4,340 (60.9%) were male; 451 (6.3%) had cirrhosis; 5,917 (83.1%) and 1,207 (16.9%) had spontaneous and nucleos(t)ide analogue (NA)-induced HBsAg seroclearance, respectively. Most patients had normal liver function at HBsAg loss. Patients with NA-induced HBsAg seroclearance were younger, and more likely to be male and cirrhotic than patients with spontaneous HBsAg loss. At a median (interquartile range) follow-up of 4.3 (2.2-7.6) years, 97 (1.6%) and 16 (1.3%) patients with spontaneous and NA-induced HBsAg loss developed HCC, respectively. Patients who achieved NA-induced HBsAg loss had comparable HCC risk as those with spontaneous HBsAg loss (adjusted subdistribution hazard ratio 0.75, 95% CI 0.43-1.32, P = 0.323). The results remained robust in propensity score weighting and matching analyses. CONCLUSION: The HCC risk was similarly low after either spontaneous or NA-induced HBsAg seroclearance in a territory-wide cohort of patients with CHB who had cleared HBsAg.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Yip TC, Wong VW, Tse YK, et al. Similarly low risk of hepatocellular carcinoma after either spontaneous or nucleos(t)ide analogue-induced hepatitis B surface antigen loss. Aliment Pharmacol Ther. 2020. PMID: 33222272. doi:10.1111/apt.16174

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。